Home › Lung Cancer › Oklahoma
Lung Cancer clinical trials in Oklahoma
20 studies for Lung Cancer are looking for participants at sites in Oklahoma.
Cities in Oklahoma
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingPhase 3
Ages 70 and older · All sexes · Updated Oct 1, 2026 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT04181060Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers
- Site 101, Oklahoma City
RecruitingObservational studyHealthy volunteers welcome
Ages 30 to 80 · All sexes · Updated Sep 11, 2026 · NCT06816121The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06500481Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05624996Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05433142A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
18 Minutes · All sexes · Updated May 5, 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT06616584SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Hightower Clinical, Oklahoma City
RecruitingObservational study
Ages 50 and older · All sexes · Updated Aug 5, 2025 · NCT06122077From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.